» Articles » PMID: 31250215

Metabolic Profiling in Children with Autism Spectrum Disorder with and Without Mental Regression: Preliminary Results from a Cross-sectional Case-control Study

Overview
Journal Metabolomics
Publisher Springer
Specialty Endocrinology
Date 2019 Jun 29
PMID 31250215
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: It is challenging to establish the mechanisms involved in the variety of well-defined clinical phenotypes in autism spectrum disorder (ASD) and the pathways involved in their pathogeneses.

Objectives: The aim of the present study was to evaluate the metabolomic profiles of children with ASD subclassified by mental regression (AR) phenotype and with no regression (ANR).

Methods: The present study was a cross-sectional case-control study. Thirty children aged 2-6 years with ASD were included: 15 with ANR and 15 with AR. In addition, a control group of 30 normally developing children was selected and matched to the ASD group by sex and age. Plasma samples were analyzed with a metabolomics single platform methodology based on liquid chromatography-mass spectrometry. Univariate and multivariate analysis, including orthogonal partial least squares-discriminant analysis modeling and Shared-and-Unique-Structures plots, were performed using MetaboAnalyst 4.0 and SIMCA-P 15. The primary endpoint was the metabolic signature profiling among healthy children and autistic children and their subgroups.

Results: Metabolomic profiles of 30 healthy children, 15 ANR and 15 AR were compared. Several differences between healthy children and children with ASD were detected, involving mainly amino acid, lipid and nicotinamide metabolism. Furthermore, we report subtle differences between the ANR and AR groups.

Conclusions: In this study, we report, for the first time, the plasmatic metabolomic profiles of children with ASD, including two different phenotypes based on mental regression status. The use of a liquid chromatography-mass spectrometry platform approach for metabolomics in ASD children using plasma appears to be very efficient and adds further support to previous findings in urine. Furthermore, the present study documents several changes related to amino acid, NAD and lipid metabolism that, in some cases, such as arginine and glutamate pathway alterations, seem to be associated with the AR phenotype. Further targeted analyses are needed in a larger cohort to validate the results presented herein.

Citing Articles

Neurodegeneration in Autism: A Study of Clusterin, Very Long-Chain Fatty Acids, and Carnitine.

Yurumez E, Cikili-Uytun M, Kaymak B, Dogan O, Ozturk H, Baysar-Kanoglu B J Mol Neurosci. 2025; 75(1):18.

PMID: 39932645 DOI: 10.1007/s12031-024-02303-6.


Indoxyl Sulfate and Autism Spectrum Disorder: A Literature Review.

Hill Z, Flynn C, Adams J Int J Mol Sci. 2024; 25(23).

PMID: 39684683 PMC: 11641216. DOI: 10.3390/ijms252312973.


Metabolic and Inflammatory Profiles in Children and Adolescents with Autism Spectrum Disorder: A Cross-Sectional Study.

Gaspar J, Ferreira J, Carvalho H, Toscano C Brain Sci. 2024; 14(11).

PMID: 39595815 PMC: 11592014. DOI: 10.3390/brainsci14111052.


Genomic insights and advanced machine learning: characterizing autism spectrum disorder biomarkers and genetic interactions.

Nahas L, Datta A, Alsamman A, Adly M, Al-Dewik N, Sekaran K Metab Brain Dis. 2023; 39(1):29-42.

PMID: 38153584 PMC: 10799794. DOI: 10.1007/s11011-023-01322-3.


Effect of Regular Consumption of a Miraculin-Based Food Supplement on Taste Perception and Nutritional Status in Malnourished Cancer Patients: A Triple-Blind, Randomized, Placebo-Controlled Clinical Trial-CLINMIR Pilot Protocol.

Lopez-Plaza B, Gil A, Menendez-Rey A, Bensadon-Naeder L, Hummel T, Feliu-Batlle J Nutrients. 2023; 15(21).

PMID: 37960292 PMC: 10648678. DOI: 10.3390/nu15214639.


References
1.
Mussap M, Noto A, Fanos V . Metabolomics of autism spectrum disorders: early insights regarding mammalian-microbial cometabolites. Expert Rev Mol Diagn. 2016; 16(8):869-81. DOI: 10.1080/14737159.2016.1202765. View

2.
Garcia-Aloy M, Llorach R, Urpi-Sarda M, Jauregui O, Corella D, Ruiz-Canela M . A metabolomics-driven approach to predict cocoa product consumption by designing a multimetabolite biomarker model in free-living subjects from the PREDIMED study. Mol Nutr Food Res. 2014; 59(2):212-20. DOI: 10.1002/mnfr.201400434. View

3.
Wang H, Liang S, Wang M, Gao J, Sun C, Wang J . Potential serum biomarkers from a metabolomics study of autism. J Psychiatry Neurosci. 2015; 41(1):27-37. PMC: 4688025. DOI: 10.1503/jpn.140009. View

4.
Kaluzna-Czaplinska J, Jozwik-Pruska J, Chirumbolo S, Bjorklund G . Tryptophan status in autism spectrum disorder and the influence of supplementation on its level. Metab Brain Dis. 2017; 32(5):1585-1593. PMC: 5596045. DOI: 10.1007/s11011-017-0045-x. View

5.
Khaselev N, Murphy R . Structural characterization of oxidized phospholipid products derived from arachidonate-containing plasmenyl glycerophosphocholine. J Lipid Res. 2000; 41(4):564-72. View